Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00470262
First received: May 4, 2007
Last updated: June 9, 2016
Last verified: June 2016
Results First Received: June 27, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Basic Science
Conditions: Metabolic Syndrome X
Prediabetic State
Interventions: Drug: Fenofibrate 145mg PO QD
Drug: Pioglitazone 45 mg PO QD

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Fenofibrate Treatment with fenofibrate 145mg PO QD
Piolitazone 45 mg PO QD + Fenofibrate 145mg PO QD Pioglitazone and Fenofibrate: Subjects will be randomized to a combination of both fenofibrate(145mg PO QD) and pioglitazone 45 mg PO QD

Participant Flow:   Overall Study
    Fenofibrate     Piolitazone 45 mg PO QD + Fenofibrate 145mg PO QD  
STARTED     15     12  
COMPLETED     13     12  
NOT COMPLETED     2     0  
Withdrawal by Subject                 2                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Fenofibrate 145 mg PO QD Treatment fenofibrate 145 mg PO QD in subjects with pre diabetes
Fenofibrate 145 mg PO QD and Pioglitazone 45mg PO QD Treatment with Fenofibrate 145 mg PO QD and Pioglitazone 45mg PO QD in subjects with pre diabetes
Total Total of all reporting groups

Baseline Measures
    Fenofibrate 145 mg PO QD     Fenofibrate 145 mg PO QD and Pioglitazone 45mg PO QD     Total  
Number of Participants  
[units: participants]
  15     12     27  
Age  
[units: years]
Mean (Standard Deviation)
  48.69  (8.46)     44.67  (11.49)     46.76  (10.03)  
Gender  
[units: participants]
     
Female     6     10     16  
Male     9     2     11  
Region of Enrollment  
[units: participants]
     
United States     15     12     27  
BMI  
[units: kg/m^2]
Mean (Standard Deviation)
  34.06  (3.51)     33.93  (3.49)     33.99  (3.43)  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Insulin Sensitivity   [ Time Frame: 3 months ]

2.  Secondary:   IMCL   [ Time Frame: 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Neda Rasouli
Organization: Denver VA Medical Center
phone: 303-399-8020 ext 4314
e-mail: neda.rasouli@ucdenver.edu



Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00470262     History of Changes
Other Study ID Numbers: ENDA-020-06S
09-0710 ( Other Identifier: COMIRB )
Study First Received: May 4, 2007
Results First Received: June 27, 2014
Last Updated: June 9, 2016
Health Authority: United States: Federal Government